✦ Clinical Takeaway ✦
No actionable clinical change; audiologists should be aware that Sony OTC hearing aids will no longer be available for patient referral and that the OTC landscape continues to shift.
✦ Why It Matters ✦
Sony's exit highlights the ongoing difficulty large consumer-electronics brands face in sustaining OTC hearing aid business, raising questions about the long-term competitive viability of the OTC category.
✦ Key Points ✦
- 01Sony has discontinued sales of its hearing aids, exiting the OTC hearing aid market.
- 02WS Audiology (WSA), Sony's OTC partner, is reassessing its OTC market strategy.
- 03The move signals challenges for consumer-electronics companies entering the hearing aid space.
- 04Patients currently using Sony hearing aids will need alternative device options.
- 05The OTC hearing aid market remains unsettled following the 2022 FDA rule enabling OTC sales.
✦ Claims & Evidence ✦
ClaimEvidenceSupport
Sony has discontinued sales of its hearing aids.
press releasesupportedWS Audiology is outlining next strategic steps for the OTC market following Sony's exit.
quotepartially supported
